TPST - Tempest to Report New and Updated TPST-1120 Randomized Combination Study Data

2023-10-11 07:47:29 ET

DENVER, Colo., Oct 11, 2023 ( www.247marketnews.com )- Tempest Therapeutics, Inc. (NASDAQ: TPST) stated, after yesterday’s market close, that it plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) this morning, in a premarket press release, followed by a webcasted conference call with associated slide presentation at 8:30 a.m. EDT.

Tempest Therapeutics is trading at $0.9701, up $0.7302 (+304.38%), on 13.8M premarket shares traded.

Its 52-week range is $0.17 to $4.2144. This move is a massive trend reversal from yesterday’s 52-week low and if the report catches some shorts off guard, it may have some more room to run.

24/7 MARKET …

The post Tempest to Report New and Updated TPST-1120 Randomized Combination Study Data appeared first on 24/7 Market News .

For further details see: